Copper-64-labeled antibodies for PET imaging.

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmaceutical Chemistry

Background:

• Positron emission tomography (PET) offers higher sensitivity for tumor imaging than conventional methods.
• Radiolabeled monoclonal antibodies are promising for targeted cancer detection.
• Copper-64 (64Cu) is a positron-emitting radionuclide suitable for PET imaging.

Purpose of the Study:

• To evaluate 64Cu-labeled 1A3 monoclonal antibody and its fragments as potential PET imaging agents for colorectal cancer.
• To compare the efficacy of 64Cu-labeled 1A3 with other radiolabeled versions (111In, 125I).

Main Methods:

• Labeling of 1A3 antibody and its F(ab')2 fragments with 64Cu using Br-benzyl-TETA.
• Biodistribution studies in tumor-bearing hamsters comparing 64Cu-labeled agents with 111In- and 125I-labeled counterparts.
• Calculation of human dosimetry from rat biodistribution data for 64Cu- and 123I-labeled 1A3 and fragments.

Main Results:

• 64Cu-labeled intact 1A3 and its fragments demonstrated superior tumor uptake in hamsters compared to 111In- and 125I-labeled versions.
• High kidney uptake of 64Cu-benzyl-TETA-1A3-F(ab')2 limited its immediate clinical applicability.
• 64Cu-benzyl-TETA-1A3 showed promising results for PET imaging of colorectal cancer.

Conclusions:

• 64Cu-labeled 1A3 antibody is a viable candidate for PET imaging of colorectal cancer.
• Further investigation is needed to optimize antibody fragments due to kidney uptake issues.
• The study highlights the potential of 64Cu in developing targeted radiopharmaceuticals for cancer diagnostics.